| Literature DB >> 30503283 |
Zi-Fu Wang1, Andrei Ursu1, Jessica L Childs-Disney1, Rea Guertler1, Wang-Yong Yang1, Viachaslau Bernat1, Suzanne G Rzuczek1, Rita Fuerst1, Yong-Jie Zhang2, Tania F Gendron2, Ilyas Yildirim3, Brendan G Dwyer1, Joseph E Rice4, Leonard Petrucelli2, Matthew D Disney5.
Abstract
The most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) is an expanded G4C2 repeat [(G4C2)exp] in C9ORF72. ALS/FTD-associated toxicity has been traced to the RNA transcribed from the repeat expansion [r(G4C2)exp], which sequesters RNA-binding proteins (RBPs) and undergoes repeat-associated non-ATG (RAN) translation to generate toxic dipeptide repeats. Using in vitro and cell-based assays, we identified a small molecule (4) that selectively bound r(G4C2)exp, prevented sequestration of an RBP, and inhibited RAN translation. Indeed, biophysical characterization showed that 4 selectively bound the hairpin form of r(G4C2)exp, and nuclear magnetic resonance spectroscopy studies and molecular dynamics simulations defined this molecular recognition event. Cellular imaging revealed that 4 localized to r(G4C2)exp cytoplasmic foci, the putative sites of RAN translation. Collectively, these studies highlight that the hairpin structure of r(G4C2)exp is a therapeutically relevant target and small molecules that bind it can ameliorate c9ALS/FTD-associated toxicity.Entities:
Keywords: RNA; RNA folding; amyotrophic lateral sclerosis; c9ALS/FTD; chemical biology; drug design; frontotemporal dementia; nucleic acids; small molecules
Mesh:
Substances:
Year: 2018 PMID: 30503283 PMCID: PMC6386614 DOI: 10.1016/j.chembiol.2018.10.018
Source DB: PubMed Journal: Cell Chem Biol ISSN: 2451-9448 Impact factor: 8.116